Figure 2.

Survival of patients diagnosed with HER2-positive disease in the southeast Netherlands diagnosed in 2005–2007, receiving trastuzumab. Kaplan-Meier estimates of disease-free survival (A) and overall survival (B) of patients treated with 1 year trastuzumab versus no trastuzumab in real life irrespective of eligibility according to 2005 guidelines. Disease-free survival (C) and overall survival (D) of patients treated with or without trastuzumab while having an indication according to 2005 Dutch guidelines. Disease-free survival (E) and overall survival (F) of patients treated with or without trastuzumab with no indication according to 2005 Dutch guidelines. Disease-free survival included recurrence of breast cancer at any site, ipsilateral or contralateral breast cancer, second non-breast malignant disease, or death from any cause. Overall survival is defined as the interval from the date of first diagnosis to the date of death or date of last follow-up.

Abbreviation: Ind., Indication.